Biosignatures of cognitive basic symptoms mark a distinct neurodevelopmental pathway to schizophrenia
Nikolaos Koutsouleris·Frauke Schultze-Lutter·Maria Fernanda Urquijo-Castro·Dominic Dwyer·Paris Alexandros Lalousis·Lisa Hahn·David Popovic·C. Maj·Clara Vetter·Wulf Rössler·Katharine Chisholm·Alexandra Korda·P Falkai·Shalaila S. Haas·Karsten Heekeren·Raimo K. R. Salokangas·L. Neuner·Med Riecher-Rössler·Clara Weyer·R. Lencer·Theresa Lichtenstein·Jarmo Hietala·Nora Penzel·Paolo Brambilla·Alessandro Bertolino·Stephen J Wood·Stefan Borgwardt·Rachel Upthegrove·Georg Romer·Christos Pantelis·Lana Kambeitz-Ilankovic·Stephan Ruhrmann·Udo Dannlowski·Joseph Kambeitz·Markus Noethen·Eva Meisenzahl·Madalina Buciuman·Linda A Antonucci·Anastasia Theodoridou
Efforts to predict schizophrenia risk using biological data have been hampered by the heterogeneity of current "clinical-high-risk" (CHR-P) criteria, which pool phenomenologically and biologically distinct syndromes under a single label. In particular, the field has focused almost exclusively on ultra-high-risk (UHR) symptoms, while cognitive basic symptoms (COGDIS)-despite their close alignment with schizophrenia's core features such as formal thought disorder-have remained underutilised. To da